A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

NCT03494179 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: ICP-022

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.